Spero Therapeutics Announces Closing of Initial Public Offering
November 06 2017 - 4:01PM
Spero Therapeutics, Inc., a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing and
commercializing novel treatments for multi-drug resistant bacterial
infections, today announced the closing of its initial public
offering of 5,500,000 shares of its common stock at a public
offering price of $14.00 per share, before underwriting discounts
and commissions. In addition, Spero Therapeutics, Inc. has
granted the underwriters a 30-day option to purchase up to 825,000
additional shares of its common stock at the initial public
offering price. The shares began trading on The Nasdaq Global
Select Market on November 2, 2017 under the ticker symbol
“SPRO.”
BofA Merrill Lynch, Cowen and Stifel acted as joint book-running
managers for the offering. Oppenheimer & Co. acted as a
co-manager for the offering.
A registration statement relating to these securities has been
filed with, and declared effective by, the Securities and Exchange
Commission. The offering was made by means of a prospectus.
Copies of the final prospectus relating to this offering may be
obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College
Street, 3rd floor, Charlotte, NC 28255-0001, Attention: Prospectus
Department, or by email at dg.prospectus_requests@baml.com; from
Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus
Department, or by telephone at (631) 274-2806; and from Stifel,
Nicolaus & Company, Incorporated, Attention: Syndicate, One
Montgomery Street, Suite 3700, San Francisco, CA 94104, or by
telephone at (415) 364-2720 or by email at
syndprospectus@stifel.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Spero
Spero Therapeutics is a multi-asset, clinical-stage
biopharmaceutical company focused on identifying, developing and
commercializing novel treatments for multi-drug resistant bacterial
infections.
Spero Media and Investor Contact
Sharon KlahreDirector, Investor
Relations857-242-1547IR@sperotherapeutics.com
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spero Therapeutics (NASDAQ:SPRO)
Historical Stock Chart
From Apr 2023 to Apr 2024